Study of HRS-2189 Combined HRS-5041 in Prostate Cancer
NCT06738745
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
90
Enrollment
OTHER
Sponsor class
Conditions
Prostate Cancer Metastatic Disease
Interventions
DRUG:
HRS-2189
DRUG:
HRS-5041
Sponsor
Fudan University